AD_____

Award Number: DAMD17-02-1-0342

TITLE: Ron in Breast Development and Cancer

PRINCIPAL INVESTIGATOR: Susan E. Waltz, Ph.D.

CONTRACTING ORGANIZATION: University of Cincinnati
Cincinnati, OH 45267-0553

REPORT DATE: October 2005

TYPE OF REPORT: Annual Summary   **20060307 107**

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

REPORT DOCUMENTATION PAGE

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
01-10-2005	Annual Summary	21 Oct 004 –30 Sep 2005

4. TITLE AND SUBTITLE

Ron in Breast Development and Cancer

5a. CONTRACT NUMBER

5b. GRANT NUMBER
DAMD17-02-1-0342

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Susan E. Waltz, Ph.D.

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

University of Cincinnati
Cincinnati, OH 45267-0553

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES
Original contains color plates: ALL DTIC reproductions will be in black and white.

14. ABSTRACT

NOT PROVIDED

15. SUBJECT TERMS
Breast Cancer

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			
U	U	U	UU	16	19b. TELEPHONE NUMBER (include area code)

Table of Contents

INTRODUCTION

Activated growth factor receptor tyrosine kinases have been shown to play pivitotal roles in a variety of human cancers. In this report, our laboratory provides a direct demonstration that Ron receptor overexpression is sufficient to induce mammary transformation and is associated with a high degree of metastasis in a murine model of human breast cancer. These results are in agreement with human cancer studies documenting an upregulation of this receptor in breast tumors as well as are consistent with the correlation between Ron overexpression and an aggressive phenotype observed in node-negative breast tumors(1-3). These experiments, therefore, provide a new target for therapeutic intervention of human breast cancer. The purpose of this proposal is to determine the contribution of Ron signaling in normal mammary gland growth and development (Aim 1). This is being accomplished by contrasting breast development in wild-type mice compared to mice with a block in Ron signaling. Secondly, the impact of Ron signaling in the pathogenesis of oncogene-driven mammary gland tumors is being evaluated (Aim 2). This will be accomplished by monitoring tumor kinetics and downstream signaling cascades in a polyoma virus middle T antigen (pMT)-induced model of breast carcinogenesis. During the past funding cycle, studies were focused primarily on Aim 2.

BODY

The work presented in this body is a summary of the recent findings my laboratory has generated based upon studies previously reported.

Despite recent evident demonstrating a role for the Ron receptor tyrosine kinase in the tumor formation, the in vivo significance of this protein in the initiation and progression of epithelial breast tumors remains unknown. The mouse model of mammary tumorigenesis induced by MMTV-pMT has been extensively utilized to examine pathways and molecules involved in mammary tumorigenesis and metastasis, including genetic loci(4, 5); putative tumor suppressors(6, 7); and other disease modifying molecules(8-10). We have recently published a report investigating the role of Ron tyrosine kinase signaling in this mammary tumor and metastasis model(11). In this model, we found that Ron receptor signaling is important for pMT-induced mammary tumor initiation and growth. Ron signaling was shown to augment microvessel density and mammary cell proliferation, and inhibit mammary epithelial apoptosis during pMT-induced mammary tumorigenesis. Based on biochemical analyses, Ron signaling was shown to synergize with pMT induced signaling, in part, by impacting proliferative and cell survival pathways, namely MAPK and AKT activation.

To expand upon these studies, we have utilized transgenic mice overexpressing the Ron receptor tyrosine kinase selectively in the mammary epithelium. Utilizing this approach, our data demonstrate that Ron over-expression is sufficient to induce the initiation and progression of mammary tumorigenesis in vivo (Table 1). Four different transgenic lines were generated (R3, R4, R6, and R7) which overexpress Ron from the MMTV promoter. As depicted in Table 1, all female offspring carrying the transgene develop tumors with an average onset of 225 days. Moreover, the Ron-expressing mammary tumors are highly metastatic with metastases observed in the lung and liver of the majority of animals (Table 2). These studies provide direct evidence that Ron overexpression plays a critical role in both the initiation and metastatic program of mammary tumorigenesis.

Mouse Line	#Mice with Tumors/Total	Average Age of Tumor Onset, Days	Range of Onset, Days
R3	8/8	161±35.6	121-231
R4	7/7	281±34.2	226-340
R6	4/4	237±48.7	198-287
R7	11/11	231±75.3	168-386
Total:	**31/31**	**225±12.8**	**121-368**

Table 1: Overexpression of the Ron receptor tyrosine kinase induces mammary tumors. The number of mice with papable mammary tumors, the average age of tumor onset and the range of tumor onset is decpicted. Data shown are mean ± SD.

% Mice with Lung Metastases	% Mice with Liver Metastases
89.7 (42/46)	63.2 % (12/19)

Table 2: Ron overexpression results in highly metastatic mammary tumors. A majority of MMTV Ron overexpressing mice develop pulmonary lung metastases and metastatic liver disease.

Summary

Based on two complementary models of Ron signaling, namely overexpression and loss of function studies, we have shown that Ron receptor signaling is critical for mammary tumor initiation, growth, and metastatic tumor formation. Based on our published work as well as recent findings, we conclude that Ron will play a significant role in breast cancer, and may be an important therapeutic target.

KEY RESEARCH ACCOMPLISHMENTS

- Ron overexpression is sufficient to induce mammary tumor formation and growth.

- Mammary tumors overexpressing Ron are highly metastatic.

REPORTABLE OUTCOMES

Reportable outcomes resulting from the Career Development Award supported by the US Army Medical Research and Material Command are as follows:

Presentations at National Meetings:
Waltz, Susan E. Platform Presentation "Regulation of mammary gland tumorigenesis by the Ron receptor tyrosine kinas." Invited Speaker, FASEB Summer Research Conferences, Growth Factor Receptor Tyrosine Kinases in Mitogenesis, Morphogenesis, and Tumorigenesis. Tucson, Arizona, August 2005.

Maxfield, S.E.; Leonis, M.A.; Kader S.; Toney, K.; Waltz, S.E. and Goss, K.H. β-Catenin and Ron: Pathway Crosstalk in Breast Cancer. Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, La Jolla, CA, September 21-24, 2005.

Waltz, S.E.; Beauman, S.; Collins, M.; Leonis, M.; Toney, K. and Peace, B.E. Ron receptor singaling augments mammary tumorigenesis in murine models of breast cancer. Era of Hope, Department of Defense Breast Cancer Progam Meeting. Philadelphia, Pennsylvania, June 8-11, 2005.

Waltz, S.E.; Beauman, S.; Collins, M.; Leonis, M.; Toney, K. and Peace, B.E. Ron receptor singaling augments mammary tumorigenesis in murine models of breast cancer. Gordon Research Conference, Mammary Gland Biology, Salve Regina University, Newport, Rhode Island. June 12-17, 2005.

Publications:
Peace, B.E.; Toney-Earlry, K.; Collins, M.H. and Waltz, S.E. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Research. 2005 65(4)1285-1293.

Funding:
Source of Support: National Institutes of Health, R01
Assignment Number: CA100002
Title of Project: The Ron receptor in mammary gland biology
Principal Investigator: Susan E. Waltz
Award Period: 6/1/04-5/31/09
Total Direct Cost: $922,500
Percent Effort: 40%
Peer Reviewed, National, Scored 4.8 percentile

CONCLUSIONS

Our data indicate that Ron receptor signaling may be a new and important therapeutic target in our fight against breast cancer. We have demonstrated that Ron is expressed in the normal mammary epithelium and its expression is increased in a model of oncogene-induced breast cancer. Moreover, we have shown that Ron signaling is sufficient to induce mammary

transformation and metastatic tumor progression. These results are consistent with data observed in human and feline cancers. This data is the first to directly demonstrate a novel role for this receptor in the mammary gland. As we learn more about Ron regulated signaling events in the breast, we will be in a better position to understand how this organ develops and the processes involved in mammary tumorigenesis and metastasis.

REFERENCES

1. De Maria, R., Maggiora, P., Biolatti, B., Prat, M., Comoglio, P.M., Castagnaro, M., and Di Renzo, M.F. 2002. Feline STK gene expression in mammary carcinomas. *Oncogene* 21:1785-1790.

2. Lee, W.Y., Chen, H.H., Chow, N.H., Su, W.C., Lin, P.W., and Guo, H.R. 2005. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. *Clin Cancer Res* 11:2222-2228.

3. Maggiora, P., Marchio, S., Stella, M.C., Giai, M., Belfiore, A., De Bortoli, M., Di Renzo, M.F., Costantino, A., Sismondi, P., and Comoglio, P.M. 1998. Overexpression of the RON gene in human breast carcinoma. *Oncogene* 16:2927-2933.

4. Lifsted, T., Le Voyer, T., Williams, M., Muller, W., Klein-Szanto, A., Buetow, K.H., and Hunter, K.W. 1998. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. *Int J Cancer* 77:640-644.

5. Le Voyer, T., Lu, Z., Babb, J., Lifsted, T., Williams, M., and Hunter, K. 2000. An epistatic interaction controls the latency of a transgene-induced mammary tumor. *Mamm Genome* 11:883-889.

6. Neznanov, N., Man, A.K., Yamamoto, H., Hauser, C.A., Cardiff, R.D., and Oshima, R.G. 1999. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. *Cancer Res* 59:4242-4246.

7. Granovsky, M., Fata, J., Pawling, J., Muller, W.J., Khokha, R., and Dennis, J.W. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. *Nat Med* 6:306-312.

8. Baribault, H., Wilson-Heiner, M., Muller, W., Penner, J., and Bakhiet, N. 1997. Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. *Transgenic Res* 6:359-367.

9. Vomachka, A.J., Pratt, S.L., Lockefeer, J.A., and Horseman, N.D. 2000. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. *Oncogene* 19:1077-1084.

10. Bugge, T.H., Lund, L.R., Kombrinck, K.K., Nielsen, B.S., Holmback, K., Drew, A.F., Flick, M.J., Witte, D.P., Dano, K., and Degen, J.L. 1998. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. *Oncogene* 16:3097-3104.

11. Peace, B.E., Toney-Earley, K., Collins, M.H., and Waltz, S.E. 2005. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. *Cancer Res* 65:1285-1293.

Ron Receptor Signaling Augments Mammary Tumor Formation and Metastasis in a Murine Model of Breast Cancer

Belinda E. Peace,[1] Kenya Toney-Earley,[1] Margaret H. Collins,[2] and Susan E. Waltz[1]

Departments of [1]Surgery and [2]Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Abstract

The tyrosine kinase receptor Ron has been implicated in several types of cancer, including overexpression in human breast cancer. This is the first report describing the effect of Ron signaling on tumorigenesis and metastasis in a mouse model of breast cancer. Mice with a targeted deletion of the Ron tyrosine kinase signaling domain (TK−/−) were crossed to mice expressing the polyoma virus middle T antigen (pMT) under the control of the mouse mammary tumor virus promoter. Both pMT-expressing wild-type control (pMT+/− TK+/+) and pMT+/− TK−/− mice developed mammary tumors and lung metastases. However, a significant decrease in mammary tumor initiation and growth was found in the pMT+/− TK−/− mice compared with controls. An examination of mammary tumors showed that there was a significant decrease in microvessel density, significantly decreased cellular proliferation, and a significant increase in terminal deoxynucleotidyl transferase–mediated nick end labeling–positive staining in mammary tumor cells from the pMT+/− TK−/− mice compared with the pMT+/− TK+/+ mice. Biochemical analyses on mammary tumor lysates showed that whereas both the pMT-expressing TK+/+ and TK−/− tumors have increased Ron expression compared with normal mammary glands, the pMT-expressing TK−/− tumors have deficits in mitogen-activated protein kinase and AKT activation. These results indicate that Ron signaling synergizes with pMT signaling to induce mammary tumor formation, growth, and metastasis. This effect may be mediated in part through the regulation of angiogenesis and through proliferative and cell survival pathways regulated by mitogen-activated protein kinase and AKT. (Cancer Res 2005; 65(4): 1285-93)

Introduction

Ron is one of a unique family of receptor tyrosine kinases, along with the proto-oncogene *Met*, and the avian oncogene *Sea* (1, 2). Ron is the receptor for hepatocyte growth factor–like protein/macrophage stimulating protein (3–6). Binding of hepatocyte growth factor–like protein to Ron induces phosphorylation of key tyrosine residues in the intracellular catalytic domain, followed by phosphorylation of tyrosine residues at the carboxyl terminal that provide docking sites for downstream adapter signal molecules (7–9). Ron activation by ligand binding has been shown to promote responses important for tumorigenesis and metastasis, including cell-cell dissociation (scattering), proliferation, motility, and morphologic changes (10–12).

The oncogenic potential of overexpressed wild-type Ron or activating point mutations in Ron has been shown *in vitro* by foci formation, increased proliferation, and increased motility. *In vivo*, transformed cells overexpressing Ron produce tumors in nude mice (13). Few studies analyzing the expression of Ron in human tumors have been done to date. However, these studies suggest that Ron overexpression or constitutive activation may be important in several tumor types, including hepatocellular carcinoma, colon and colorectal cancer, and a subset of non–small cell lung cancer (14–17). Importantly, Ron overexpression and activation, indicated by increased phosphorylation, has recently been identified in human breast cancer (18). Overexpression of Ron was found in about 50% of the primary ductal and lobular carcinomas examined (35 of 74 patients), yet was barely detectable in normal breast tissue or in benign breast lesions, including papillomas and fibroadenomas. In support of an important role for Ron in breast cancer, overexpression of Ron has also been found in feline mammary tumors (19). The functions of Ron in cell culture and the presence of activated forms of Ron in tumor tissue lead to the hypothesis that Ron tyrosine kinase function may be important in mammary tumorigenesis.

We previously reported the development of mice containing the targeted deletion of the tyrosine kinase domain of Ron (20). These mice (TK−/−) are phenotypically normal, fertile, and nurse their young. However, several functional defects have been noted in these mice, including the inability to regulate inflammatory responses mediated by ligand binding and activation (20–22). To test the hypothesis that Ron receptor activation and signaling is an important factor in mammary cancer, mice with a defect in Ron signaling (TK−/− mice) were crossed to transgenic mice expressing polyoma virus middle T antigen (pMT) under the control of the mouse mammary tumor virus promoter. Female mice expressing pMT rapidly develop multifocal mammary tumors that metastasize to the lungs (23).

In this report, we show that deletion of Ron signaling produces a significant reduction in mammary tumor development induced by the pMT. Our results suggest that Ron signaling synergizes with pMT signaling to induce mammary tumor formation in this model.

Materials and Methods

Mice. Hemizygous male mice in a FVB/N background expressing pMT under the control of the mouse mammary tumor virus promoter [FVB/N-TgN(MMTVPyVT)634Mul] were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice with a deletion of the Ron tyrosine kinase domain (TK−/−) of Ron have been previously described (20). TK−/− mice were maintained in an FVB/NJ background following seven generations of back crosses. The *MMTV-pMT* transgene was maintained in a hemizygous state by crossing male transgene carriers bred to homozygosity for the deletion

of the Ron tyrosine kinase domain (pMT+/− TK−/−) to female mice (pMT−/− TK−/−) to produce the experimental group (pMT+/− TK−/−). Male mice (pMT+/− TK+/+) were crossed to wild-type females (pMT−/− TK+/+) to produce the control group (pMT+/− TK+/+). Male mice (pMT+/− TK+/+) were crossed to females homozygous for the deletion of the Ron tyrosine kinase domain (pMT−/− TK−/−) to produce *MMTV-pMT* transgenic positive, Ron kinase domain deletion heterozygous animals (pMT+/− TK+/−). Transmission of the *MMTV-pMT* transgene and the Ron genomic locus was determined by PCR using primers that have been described previously (20, 24). Only female mice were examined for tumor formation. The mice were maintained and sacrificed under approved animal care protocols in an Association for Assessment of Laboratory Animal Care–accredited facility.

Tumor Parameters. The time to the formation of a palpable tumor was determined by manual palpation. The number of glands containing tumors was determined by examination at sacrifice. The tumor burden was calculated by determining the total tumor mass at the time of sacrifice.

Mammary Tumor Histology and Immunohistochemistry. Mammary tumors were formalin fixed, processed, and paraffin embedded. Parallel 4 μm sections were used for different analyses. Sections were stained with H&E for histologic examination. Images were obtained using a Zeiss (Thornwood, NY) microscope equipped with an Axiovert digital camera. The left abdominal mammary gland was taken from mice at 49 days to evaluate proliferation in discrete tumor nodules. Proliferation of mammary cells was examined following i.p. injection of 0.1 mL of 5-bromo-2′-deoxyuridine (BrdUrd) solution 2 hours before sacrifice using a cell proliferation kit (Amersham Pharmacia Biotech, Piscataway, NJ). Paraffin-embedded mammary tissue sections were stained following the manufacturer's guidelines. Positively staining cells were visualized using a horseradish peroxidase–conjugated secondary antibody, stained with 3,3′-diaminobenzidine (DAB) (Sigma-Aldrich, St. Louis, MO), then counterstained with hematoxylin and permanently coverslipped. Measurement of the size of a tumor nodule or tumor area examined and counting the number of positively staining cells in the tumor nodule was done on a Macintosh computer using the public domain NIH Image software program (developed at the U.S. NIH and available on the Internet at http://rsb.info.nih.gov/nih-image/). Five areas per tumor from four mice per group were evaluated. The proliferation index was calculated as the number of cells incorporating BrdUrd per area of tumor nodule in square inches.

Apoptosis was evaluated by terminal deoxynucleotidyl transferase–mediated nick end labeling (TUNEL) staining using an *in situ* cell death detection kit (Roche, Indianapolis, IN) following the manufacturer's guidelines. The sections were treated with an alkaline phosphatase conjugated secondary antibody, and positively staining cells were visualized with Fast Red (Sigma-Aldrich). The slides were then mounted with Immu-Mount (Shanndon, Pittsburg, PA) for evaluation. The apoptotic index was calculated as the number of cells positive for TUNEL staining per area of tumor nodule in square inches as described for proliferation above. Three to five areas per tumor from four to six control and experimental mice were evaluated.

Staining for Ron protein in mammary tumor sections was done on formalin-fixed, paraffin-embedded sections of mammary tumors at 49 days. Antigen retrieval was done by heating the slides in a citric acid-sodium citrate buffer. Sections were stained with a mouse antibody specific to the extracellular α-chain of Ron (Ron α, BD Transduction Laboratories, San Diego, CA). The slides were developed using a horseradish peroxidase-conjugated secondary antibody (Vectastain ABC kit, Vector Laboratories, Burlingame, CA), stained with DAB, and counterstained with hematoxylin. As a negative control, a serial section was treated with normal mouse IgG in place of the primary antibody.

Microvessel staining in mammary tumor sections was done on formalin-fixed, paraffin-embedded sections of mammary tumors at 52 ± 3 days. Five to seven areas per tumor from four mice per group were evaluated. Antigen retrieval was done by heating the slides in a citric acid-sodium citrate buffer. Microvessels were visualized by staining with rabbit

anti-human von Willebrand factor (DakoCytomation, Carpinteria, CA). The slides were developed using a horseradish peroxidase conjugated secondary antibody (Vectastain ABC kit, Vector Laboratories), stained with DAB, and counterstained with hematoxylin. As a negative control, a serial section was treated with normal mouse IgG in place of the primary antibody.

Lung Histology. Lung tissue was prepared by perfusion with PBS, followed by perfusion with formalin, formalin fixed, processed, and paraffin embedded. The left lung was routinely sectioned. Four-micrometer sections were taken at 200-μm intervals along the entire lobe to obtain full coverage of this organ. Sections were stained with H&E for routine histologic examination. The number of metastases per section was counted, and the maximum number of metastases was used for statistical analysis. The lung section containing the maximum number of metastases was digitized and area measurements of the lung section and of the metastatic foci were done on a Macintosh computer using the public domain NIH Image program.

Northern Analysis. Total RNA was isolated from tumor tissue of experimental and control animals using Trizol (Invitrogen, Carlsbad, CA). RNA (30 μg) was separated on a 1.2% agarose gel, transferred to a nylon membrane, and stained with methylene blue to detect 18 and 28 S rRNA. The membrane was hybridized with a polyoma specific sequence generated by PCR using oligonucleotides that have been previously described (25).

Western Analysis. Western analysis of protein lysates from mammary tumor tissue of experimental and control mice at 55 ± 4 days was done essentially as described (13). Western membranes were probed with antibodies to either the extracellular α-chain of Ron (Ron α, BD Transduction Laboratories), phospho-mitogen-activated protein kinase (MAPK, Biosource, Camarillo, CA), MAPK (Biosource), phospho-AKT (Upstate Biotechnology, Lake Placid, NY), or AKT (Upstate Biotechnology). The anti-C4 actin antibody was a gift of Dr. James Lessard (Cincinnati Children's Hospital Medical Center, Cincinnati, OH).

Statistical Analysis. ANOVA statistical analysis was done using the StatView program (SAS Institute, Cary, NC). Growth curve differences between the two genotypes were evaluated by log rank analysis using the same statistical software package.

Results

To evaluate the impact of Ron signaling on mammary tumor formation induced by pMT, female mice with and without Ron signaling were crossed to pMT-expressing males. Female TK+/+ and TK−/− mice with and without pMT were used for further analysis.

In Fig. 1*A*, the kinetics of tumor initiation in pMT-expressing control TK+/+, experimental TK−/−, and heterozygous TK+/− mice were calculated as the percent of tumor-free mice per total number of mice observed over time. No difference between TK+/+ and TK+/− mice was observed, but there was a significant difference ($P < 0.05$) between the TK+/+ and TK−/− mice, as determined by log rank analysis. Wild-type control mice with Ron signaling exhibit a significantly increased rate of tumor initiation.

The expression of pMT in TK+/+ and TK−/− tumors was also evaluated (Fig. 1*B*). Figure 1*B* (*top*) shows a Northern analysis of total RNA from several independent pMT+/− TK+/+ and pMT+/− TK−/− tumors, hybridized with a sequence specific for pMT. Figure 1*B* (*bottom*), shows the 18S and 28S RNA from this Northern analysis to show approximately equal RNA loading. No difference in the expression of pMT between TK+/+ and TK−/− tumors was observed.

Other parameters of tumor formation were also evaluated and are summarized in Table 1. There was no difference between the control and experimental groups in the age of the animal at sacrifice. Tumors from TK+/+ mice had increased growth compared with tumors from TK−/− mice. Tumor initiation was

Figure 1. Ron signaling increases tumor initiation. *A*, The kinetics of tumor formation in control (pMT+/− TK+/+, *n* = 35) (■), heterozygous (pMT+/− TK+/−; *n* = 12) (●), and experimental (pMT+/− TK−/−; *n* = 17) (▲) mice was calculated as the percent of tumor-free mice compared with the total number of mice observed for the initiation of a palpable tumor. The difference between the curves was evaluated by a log rank analysis. No difference in tumor initiation was found between mice homozygous or heterozygous for the Ron tyrosine kinase domain. A significant different was found between the control and experimental groups (*P* < 0.05). Mice lacking Ron signaling capability exhibit a significantly decreased rate of tumor initiation (*B*). Total RNA from three pMT+/− TK+/+ and four pMT+/− TK−/− mice was subjected to Northern analysis and hybridized to a probe specific for pMT (*top*) The ethidium bromide–stained 18S and 28S is shown to evaluate loading (*bottom*).

significantly reduced in the control animals, forming tumors about a week before a palpable tumor was observed in mice devoid of Ron signaling. The number of mammary glands per mouse with frank palpable tumors was also significantly greater in TK+/+ than in TK−/− mice. The body burden of tumor (tumor mass, grams) was about half again as much in the control mice than in the Ron signaling–deficient mice over the same period of growth, showing that the growth of mammary tumors induced by pMT is augmented by the presence of Ron signaling. In a comparison of F1 hybrid animals, we found that there was no significant difference in tumor latency or tumor mass between wild-type and heterozygous Ron TK–deficient mice (Table 1). These results

suggest that the phenotypic changes observed in the TK−/− mice are a result of the Ron allele and not due to modification by other genetic loci.

Tumors were examined by light microscopy for morphologic comparison. Figure 2*A* and *B* shows representative tumors from control and experimental mice taken at 51 ± 2 days of age. The early-stage tumors from both genotypes presented as well-differentiated adenocarcinomas with minimal necrosis. Late-stage tumors (89 ± 5 days of age) from TK+/+, TK−/−, and TK+/− mice (Fig. 2*C-E*) were moderately differentiated adenocarcinomas with areas demonstrating moderate to severe cystic patterns, many with luminal secretions. Necrosis varied from minimal to extensive. In architecture and cytology, the mammary tumors from control and experimental animals were similar. However, the increased cell mass of tumor in the control animals was apparent at early stages of tumor growth (Fig. 2*A* and *B*), and remained striking even at late stages (Fig. 2*C-E*). The extensive tumor mass in heterozygous TK+/− animals resembled that seen in the control TK+/+ group.

The mammary tumors induced by pMT express Ron protein, as shown in Fig. 2*F-G*. Serial sections from a pMT +/− TK+/+ tumor are shown. A control section using normal mouse IgG in place of the primary antibody against Ron is shown in Fig. 2*F*. The lack of staining in the control section establishes the specificity of the Ron antibody. Our previous work also showed the specificity of this antibody by blocking Ron immunoreactivity with exogenously added Ron recombinant protein (26). Specific immunohistochemical staining for Ron protein in the mammary tumor section in Fig. 2*G*, indicates that Ron is expressed in the mammary epithelium during pMT-induced transformation.

Tumors arising from pMT metastasize to the lungs (23). To facilitate comparison, the entire left lung was sectioned at intervals, and each section examined for metastatic foci. Figure 3 shows a representative section of lung from control (*A* and *C*) and experimental (*B* and *D*) mice, examined at low magnification (*A* and *B*) and at high magnification (*C* and *D*). The distinctive appearance of the metastatic foci in the lung tissue is apparent. There were no morphologic differences between metastatic foci in the lungs of pMT +/− TK+/+, pMT +/− TK+/−, or pMT +/− TK−/− animals. Metastatic foci were quantitated in two ways, and the data are summarized graphically in Fig. 2*E* and *F*. The section of the left lung containing the greatest number of metastatic foci was examined, and the maximum number of foci counted, shown in Fig. 2*E*. The area covered by the metastatic foci, compared with the total area of the lung section in which they were counted, is presented in Fig. 2*F*. Although the difference is not statistically significant, there is a trend to a greater number of metastatic foci, and a larger area covered by

Table 1. Growth of mammary tumors induced by pMT is augmented by Ron signaling

Mouse genotype	Days of tumor growth	Days to a palpable tumor	No. of tumors	Body burden of tumors (g)
pMT+/− TK+/+	82 ± 6 (35)	46 ± 8 (34)	8 ± 0 (35)	4.9 ± 2.7 (35)
pMT+/− TK+/−	83 ± 6 (12)	47 ± 10 (12), *P* = 0.40	7 ± 2 (12), *P* = 0.39	4.3 ± 2.5 (12), *P* = 0.31
pMT+/− TK−/−	80 ± 8 (17)	55 ± 9 (15), *P* = 0.002	6 ± 1 (17), *P* = 0.05	3.0 ± 1.9 (17), *P* = 0.012

NOTE: The average age of the animal at sacrifice is indicated as days of tumor growth, which did not differ between genotypes. A significant decrease in the days to mammary tumor initiation and a significant increase in the number of mammary glands with tumors and in the tumor body burden (tumor mass, g) was seen in pMT+/− TK+/+ mice compared with pMT+/− TK−/− mice. No differences were observed between pMT containing TK+/+ and TK+/− mice. Data shown are mean ± SD (number of mice evaluated).

Figure 2. Mammary tumors of pMT+/− TK+/+ and pMT+/− TK−/− mice are morphologically similar but exhibit different growth. Representative sections from mammary tumors are shown at different stages of tumor growth. Tumor cells are visible in both pMT+/− TK+/+ (A) and pMT+/− TK−/− (B) mammary glands taken at 51 ± 2 days. By 89 ± 5 days of growth, the tumors show more extensive growth in pMT+/− TK+/+ (C) and pMT+/− TK+/− (E) than pMT+/− TK−/− (D) mammary glands. F-G, expression of Ron protein in pMT-induced mammary tumors. F, control section without primary antibody. G, specific staining for Ron protein in pMT+/− TK+/+ section from a tumor at 52 days of growth. Black bars, 200 μm; red bar, 50 μm.

the foci, in the lungs of the pMT +/− TK+/+ mice compared with the pMT +/− TK−/− mice. In these experiments, there was no correlation between either the tumor burden or the total number of days of tumor growth and either the number of metastatic foci or the area of the lung occupied by the metastatic foci, underscoring the complex nature of the metastatic process and suggesting that the decrease in metastatic load is not simply due to a delay in lung colonization.

The growth of the pMT +/− TK+/+ tumors compared with pMT +/− TK−/− tumors suggested that several mechanisms might be operating, either singly or collectively, to repress the growth of polyoma induced tumors in the absence of signaling from Ron. Therefore, mammary tumor sections were examined by immuno-histochemistry for angiogenesis (microvessel formation), cellular proliferation, and apoptosis.

Cellular proliferation was evaluated by immunohistochemical staining of mammary tumor sections after *in vivo* incorporation of BrdUrd. Mammary tumors were collected from mice of both genotypes between 49 and 55 days of age. The tumor collection at this early time point allowed the examination of cells in discrete tumor foci. Representative tumor sections with this proliferation marker are illustrated in Fig. 4A and B. An increased number of proliferating cells are observed in the pMT +/− TK+/+ mammary tumor Fig. 4A, compared with the pMT +/− TK−/− tumor Fig. 4B. TUNEL staining was used to analyze apoptotic cells within the mammary tumors. Representative tumor sections collected at 49 to 55 days of age containing TUNEL-positive cells are presented in Fig. 4C and D, and tumor sections collected at 89 ± 6 days are shown in Fig. 4E-G. A decreased number of TUNEL-positive are seen in the mammary tumor from the pMT +/− TK+/+ mouse (Fig. 4C and E), compared with the pMT +/− TK−/− mouse (Fig. 4D 4D and G). Equivalent numbers of TUNEL-positive cells were seen in heterozygous pMT +/− TK+/− and wild-type pMT +/− TK+/+ tumors (Fig. 4F and E).

The number of proliferating and TUNEL-positive cells were counted and normalized to the area of the tumor foci. The

summary of these measurements is presented in Table 2. A significantly greater number of proliferating cells are present in pMT-induced mammary tumors from pMT +/− TK+/+ mice compared with pMT +/− TK−/− mice ($P < 0.02$). Moreover, significantly fewer TUNEL-positive cells are present in the mammary tumors from pMT +/− TK+/+ mice than pMT +/− TK−/− mice ($P < 0.02$) at both early and late time points. No difference was seen between pMT +/− TK+/+ and pMT +/− TK+/− tumors in TUNEL-positive staining cells.

Microvessel formation in the mammary tumors was evaluated by immunohistochemical staining with endothelial cell marker, von Willebrand factor. Figure 5 shows representative tumor sections from pMT+/− TK+/+ (*A* and *B*) and pMT+/− TK−/− (*C* and *D*) mice. Serial sections treated with normal mouse IgG in place of the primary antibody (*A* and *C*) do not show vessel staining, demonstrating the specificity of this analysis. An increased number of microvessels is seen in the pMT +/− TK+/+ tumor section (Fig. 5*B*), compared with the pMT +/− TK−/− tumor (Fig. 5*D*). The number of microvessels was counted and normalized to the area of the tumor foci, to determine microvessel density. These measurements are also presented in Table 2. A significantly greater number of microvessels are present in pMT-induced mammary tumors from pMT +/− TK+/+ mice compared with pMT +/− TK−/− mice ($P < 0.02$).

To elucidate the molecular mechanism underlying this striking difference in the growth of pMT-induced mammary tumors mediated by Ron signaling, Western analyses were done (Fig. 6). Ron expression and the activation of proliferation- and apoptosis-associated molecules were evaluated.

In Fig. 6*A*, a representative Western analysis of Ron protein expression in mammary tumor and normal mammary gland lysates is shown. These analyses used an antibody that recognizes the extracellular domain of Ron, which is intact in both the TK+/+ and TK−/− mice. The same membrane was stripped and reprobed with an antibody that recognizes actin to show equivalent protein loading in each lane. Equivalent levels of Ron protein are expressed in normal mammary glands of TK+/+ (lanes 1 and 2) and TK−/− (Fig. 6, *lanes 5* and *6*)) mice. Compared to the level of Ron expression in normal mammary glands, the pMT-expressing tumors from pMT+/− TK+/+ (Fig. 6, *lanes 3* and *4*)) and pMT+/− TK−/− (Fig. 6, *lanes 7* and *8*) mice express 5-fold and 4-fold higher levels of Ron protein. The ligand for Ron is expressed in the liver, excreted into the bloodstream, and circulates in an inactive form until it is activated at the cell surface. Normal mammary tissue and mammary tumor tissue was analyzed for the presence of hepatocyte growth factor–like protein, the ligand for Ron, by Western and Northern analysis. Hepatocyte growth factor–like protein was not detected in

Figure 3. Lung metastasis of pMT–induced tumors is reduced in experimental animals lacking Ron signaling. *A* and *B*, representative whole lung sections, showing the typical appearance of metastases within the lung, are shown for pMT+/− TK+/+ (*A*) and pMT+/− TK−/− (*B*) lungs taken at 90 days of growth. Higher magnification images of representative metastases, corresponding to the outlined areas in (*A*) and (*B*) are also shown for pMT+/− TK+/+ (*C*) and pMT+/− TK−/− (*D*) lungs. No morphologic difference between lung metastases from control or experimental mice was observed (*C-D*). The extent of lung metastasis between the experimental and control animal groups was evaluated (pMT+/− TK+/+, *n* = 21; pMT+/− TK−/−, *n* = 20). The number of metastatic foci in a lung section was counted, and the maximum number of metastases observed in a section of the lung is shown (*E*). The area covered by metastatic cells compared with the total area of the lung section was also measured and these values shown in (*F*).

Figure 4. Increased proliferation and reduced TUNEL-positive staining of cells in mammary tumors from pMT+/− TK+/+ compared with pMT+/− TK−/− mice. Proliferative cells in tumor tissue were detected by immunohistochemical staining for BrdUrd incorporation. Representative sections from pMT+/− TK+/+ (*A*), and pMT+/− TK−/− (*B*) tumors taken from mice at 49 days of age. *Red arrows,* representative BrdUrd staining cells. Apoptotic cells in tumor tissue were detected by the immunohistochemical staining for TUNEL-positive cells. Representative sections from pMT+/− TK+/+ (*C*), and pMT+/− TK−/− (*D*), tumors at 51± 2 days, and from pMT+/− TK+/+ (*E*), pMT+/− TK+/− (*F*), and pMT+/− TK−/− (*G*), at 89 ± 5 days are shown. *Black arrows,* representative TUNEL-positive cells. Original magnification ×100.

mammary tissue (data not shown). This suggests that over-expression of Ron in mammary tumors leads to ligand-independent activation of this receptor and is consistent with previous findings on Ron overexpression (13).

Activation of Ron has been shown to activate MAPK, a well-known regulator of cell proliferation (27, 28). In Fig. 6*B*, a representative Western analysis of MAPK level and activation in tumor lysates from pMT+/− TK+/+ (Fig. 6, *lanes 1-3*) and pMT+/−


Figure 5. Increased microvessel density in mammary tumors from pMT+/− TK+/+ compared with pMT+/− TK−/− mice. Microvessels in tumor tissue were detected by immunohistochemical staining (Red arrows). Representative sections from pMT+/− TK+/+ (*A* and *B*), and pMT+/− TK−/− (*C* and *D*) tumors taken from mice at 52 ± 3 days of age are shown. *A* and *C*, control serial sections treated with normal mouse IgG in place of the primary antibody for pMT+/− TK+/+ (*A*) and pMT+/− TK−/− (*C*) tumors. Sections of pMT+/− TK+/+ (*B*) and pMT+/− TK−/− (*D*) tumors stained with an anti-von Willebrand factor antibody. Magnification, ×100.

Table 2. Ron signaling regulates cell growth, TUNEL staining, and microvessel density in mammary tumors induced by pMT

Mouse genotype	Proliferative cells (in^2)	TUNEL-positive cells (in^2)	Microvessel density microvessels (in^2)
pMT+/− TK+/+	10.2 ± 4.7	2.1 ± 0.8, 1.5 ± 0.8[a]	4.1 ± 0.39
pMT+/− TK+/−	ND	1.1 ± 0.7,[a] $P > 0.05$	ND
pMT+/− TK−/−	4.7 ± 2.7, $P < 0.02$	3.7 ± 1.5, $P < 0.02$; 2.3 ± 0.7,[a] $P < 0.002$	2.6 ± 0.16, $P < 0.02$

NOTE: A significant increase in proliferation, a significant decrease in TUNEL positive cells, and a significant increase in microvessel density was seen in mammary tumors in the pMT +/− TK+/+ mice compared with pMT +/− TK−/− mice. No differences were observed between pMT-containing TK+/+ and TK+/− mice. Tumors were collected at 51 ± 2 days or at 89 ± 5 days ([a]). Data shown are mean ± SD. Abbreviation: ND, not determined.

TK−/− (Fig. 6, *lanes 4-6*) mice is shown. Phosphorylated MAPK (p44 and p42) are indicated. The same blot was stripped and reprobed with an antibody that recognizes nonphosphorylated p44 and p42 MAPK to determine the total amount of MAPK in each sample. Equivalent amounts of MAPK are found in pMT+/− TK+/+ and pMT+/− TK−/− tumors. However, the phosphorylated form of MAPK is 1.5-fold greater in pMT+/− TK+/+ tumors than in pMT+/− TK−/− tumors.

Phosphatidylinositol-3-kinase (PI3K) has also been shown to interact directly with the Ron receptor (7, 29) resulting in the downstream activation of AKT and increased cell proliferation (30, 31). In Fig. 6C, a representative Western analysis of AKT level and activation in tumor lysates from pMT+/− TK+/+ (Fig. 6, *lanes 1-3*) and pMT+/− TK−/− (Fig. 6, *lanes 4-6*) mice is shown. Phosphorylated AKT (p60) is indicated. The same blot was stripped and reprobed with an antibody that recognizes nonphosphorylated AKT to determine the total amount of AKT in each sample. Equivalent amounts of AKT are found in pMT+/− TK+/+ and pMT+/− TK−/− tumors. However, the phosphorylated form of AKT is 1.5-fold greater in pMT+/− TK+/+ tumors than in pMT+/− TK−/− tumors.

Discussion

The experiments detailed in this report are the first to directly examine the impact of Ron receptor tyrosine kinase signaling on mammary tumor initiation and growth, by using an experimental mouse model of breast cancer induced by mammary-specific expression of pMT. In this model, lack of Ron signaling significantly increases tumor latency, significantly reduces tumor growth, and may reduce tumor metastasis. Significantly increased cellular proliferation, reduced TUNEL-positive staining, and increased microvessel formation is found in wild-type pMT-expressing tumors compared with pMT-induced tumors lacking Ron signaling. The tumors produced by pMT overexpress Ron protein. Increased activation of MAPK and AKT is seen in wild-type pMT expressing tumors compared with pMT-induced tumors lacking Ron signaling. Although the formal possibility exists that a recessive linked locus may be responsible for the effect attributed to the deletion of the Ron tyrosine kinase domain, the lack of any difference in tumor characteristics between the wild-type and heterozygous Ron TK-deficient mice strongly argues that the phenotypic and biochemical changes observed in the TK−/− mice are a result of the Ron allele and not due to modification by other genetic loci.

Multiple mechanisms by which Ron signaling may synergize with pMT signaling to influence tumor growth have been revealed by our immunohistochemical and biochemical analysis of pMT-expressing tumors produced in the presence and absence

of an intact tyrosine kinase domain of Ron. First, overexpression of Ron protein is seen in the mammary tumors induced by pMT. Interestingly, a recent series of experiments in our laboratory has determined that activation of Ras in a mouse model of skin carcinogenesis also up-regulates Ron (32). Our previous experiments have shown that Ron overexpression is accompanied by constitutive activation of the receptor, transformation, and increased cell proliferation (13). In the absence of the tyrosine kinase domain, the overexpression of the truncated receptor will not amplify downstream transformative and proliferative signals.


Figure 6. Western analysis of mammary tissue lysates. *A*, representative Western analysis of Ron protein expression in tumor lysates from pMT+/− TK+/+ (*lanes 3 and 4*) and pMT+/− TK−/− mice (*lanes 7 and 8*), compared with non-tumor-bearing TK+/+ (*lanes 1 and 2*) and TK−/− (*lanes 5 and 6*) mice is shown. The same membrane was stripped and reprobed with an antibody that recognizes actin to show equivalent protein loading in each lane. *B*, representative Western analysis of MAPK level and activation in tumor lysates from pMT+/− TK+/+ (*lanes 1-3*) and pMT+/− TK−/− (*lanes 4-6*) mice is shown. Phosphorylated MAPK (*p-MAPK*, p44 and p42) are indicated. The same membrane was stripped and reprobed with an antibody that recognizes nonphosphorylated p44 and p42 MAPK to determine the total amount of MAPK in each sample. *C*, representative Western analysis of AKT level and activation in tumor lysates from pMT+/− TK+/+ (*lanes 1-3*) and pMT+/− TK−/− (*lanes 4-6*) mice is shown. Phosphorylated AKT (*p-AKT*, p60) is indicated. The same blot was stripped and reprobed with an antibody that recognizes nonphosphorylated AKT to determine the total amount of AKT in each sample.

Second, the lack of Ron signaling has an apparent effect on angiogenesis within the mammary tumors induced by pMT. There has been considerable research conducted on the relationship between angiogenesis and tumor growth. Angiogenesis within human mammary tumors has been correlated with metastatic disease, and poor prognosis (33). Polyoma middle T–induced tumors have been shown to be poorly perfused in relationship to their growth (34), and yet tumor growth in this model has been shown to be influenced by the ability of the tumor to recruit microvessels (35). The dramatic reduction in microvessels seen in the pMT+/− TK−/− tumors compared with the pMT+/− TK+/+ tumors, coupled with their reduced growth rate, suggests that Ron signaling may play a role in promoting angiogenesis in this mammary tumor.

Third, the parallel increases in cellular proliferation and cell survival may be mediated by increased activation of MAPK and AKT acting in concert in pMT+/− TK+/+ mammary tumors, compared with tumors in which Ron signaling is absent. Activation of AKT is coupled to activation of PI3K. Polyoma middle T antigen transformation is highly dependent on PI3K. Mice carrying a mutation abolishing the binding site for PI3K on pMT develop mammary gland hyperplasias that are highly apoptotic, and only develop focal tumors at a late time point (36). A reintroduction of activated AKT into the mouse strain decoupled from pMT-PI3K interaction restored and accelerated mammary tumorigenesis, with a concomitant reduction in apoptosis in the mammary tumor (36). Ron has previously been shown to mediate both apoptotic and growth signals (7); however, the role of Ron in cell survival may be cell type dependent (7, 22). Adherent epithelial cell survival stimulated by ligand binding of Ron was found to depend on both MAPK and PI3K/AKT activation, and each pathway independently contributed to overall cell survival (37). These experiments support the argument that the increased activation of both MAPK and AKT in pMT+/− TK+/+ tumors, compared with pMT+/− TK−/− tumors, jointly contributes to the increased proliferation, decreased apoptosis, and overall increased tumor growth.

The mouse model of mammary tumorigenesis induced by *MMTV-pMT* has been extensively used to examine pathways and molecules involved in mammary tumorigenesis and metastasis, including genetic loci (38, 39), putative tumor suppressors (40, 41), and other disease-modifying molecules (24, 42, 43). Our report is the first to investigate the role of Ron tyrosine kinase signaling in this mammary tumor and metastasis model. We conclude that Ron will play a significant role in breast cancer and may be an important therapeutic target.

References

1. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195–202.
2. Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood 1994;83:3160–69.
3. Han S, Degen SJ. Genomic organization, chromosomal localization and developmental expression of hepatocyte growth factor-like protein. EXS 1993;65:81–105.
4. Yoshimura T, Yuhki N, Wang MH, Skeel A, Leonard EJ. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J Biol Chem 1993;268:15461–8.
5. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994;13:3524–32.
6. Wang MH, Iwama A, Skeel A, Suda T, Leonard EJ. The murine stk gene product, a transmembrane protein tyrosine kinase, is a receptor for macrophage-stimulating protein. Proc Natl Acad Sci U S A 1995;92:3933–7.
7. Iwama A, Yamaguchi N, Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. Embo J 1996;15:5866–75.
8. Danilkovitch A, Leonard EJ. Kinases involved in MSP/RON signaling. J Leukoc Biol 1999;65:345–8.
9. Xiao ZQ, Chen YQ, Wang MH. Requirement of both tyrosine residues 1330 and 1337 in the C-terminal tail of the RON receptor tyrosine kinase for epithelial cell scattering and migration. Biochem Biophys Res Commun 2000;267:669–75.
10. Wang MH, Dlugosz AA, Sun Y, Suda T, Skeel A, Leonard EJ. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res 1996;226:39–46.
11. Waltz SE, McDowell SA, Muraoka RS, et al. Functional characterization of domains contained in hepatocyte growth factor-like protein. J Biol Chem 1997;272:30526–37.
12. Mera A, Suga M, Ando M, Suda T, Yamaguchi N. Induction of cell shape changes through activation of the interleukin-3 common β chain receptor by the RON receptor-type tyrosine kinase. J Biol Chem 1999;274:15766–74.
13. Peace BE, Hughes MJ, Degen SJ, Waltz SE. Point mutations and overexpression of Ron induce transformation, tumor formation, and metastasis. Oncogene 2001;20:6142–51.
14. Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997;26:59–66.
15. Okino T, Egami H, Ohmachi H, et al. Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. Int J Oncol 1999;15:709–14.
16. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000;21:1507–12.
17. Willett CG, Wang MH, Emanuel RL, et al. Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. Am J Respir Cell Mol Biol 1998;18:489–96.
18. Maggiora P, Marchio S, Stella MC, et al. Overexpression of the RON gene in human breast carcinoma. Oncogene 1998;16:2927–33.
19. De Maria R, Maggiora P, Biolatti B, et al. Feline STK gene expression in mammary carcinomas. Oncogene 2002;21:1785–90.
20. Waltz SE, Eaton L, Toney-Earley K, et al. Ron-mediated cytoplasmic signaling is dispensable for viability but is required to limit inflammatory responses. J Clin Invest 2001;108:567–76.
21. McDowell SA, Mallakin A, Bachurski CJ, et al. The role of the receptor tyrosine kinase Ron in nickel-induced acute lung injury. Am J Respir Cell Mol Biol 2002;26:99–104.
22. Leonis MA, Toney-Earley K, Degen SJ, Waltz SE. Deletion of the Ron receptor tyrosine kinase domain in mice provides protection from endotoxin-induced acute liver failure. Hepatology 2002;36:1053–60.
23. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954–61.
24. Bugge TH, Lund LR, Kombrinck KK, et al. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998;16:3097–104.
25. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995;270:30093–101.
26. Hess KA, Waltz SE, Chan EL, Degen SJ. Receptor tyrosine kinase Ron is expressed in mouse reproductive tissues during embryo implantation and is important in trophoblast cell function. Biol Reprod 2003;68:1267–75.
27. Santoro MM, Penengo L, Minetto M, Orecchia S, Cilli M, Gaudino G. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 1998;17:741–9.
28. Santoro MM, Collesi C, Grisendi S, Gaudino G, Comoglio PM. Constitutive activation of the RON gene promotes invasive growth but not transformation. Mol Cell Biol 1996;16:7072–83.
29. Wang MH, Montero-Julian FA, Dauny I, Leonard EJ. Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein. Oncogene 1996;13:2167–75.
30. Agazie Y, Ischenko I, Hayman M. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene. Oncogene 2002;21:697–707.
31. Finkelstein LD, Ney PA, Liu QP, Paulson RF, Correll PH. Sf-Stk kinase activity and the Grb2 binding site are

required for Epo-independent growth of primary erythroblasts infected with Friend virus. Oncogene 2002;21:3562–70.

32. Chan EL, Peace BE, Collins MH, Toney-Early K, Waltz SE. The Ron receptor tyrosine kinase augments Ras-mediated cell growth and malignant conversion. Oncogene 2004 Nov 08 [Epub ahead of print].

33. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991;324: 1–8.

34. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298–305.

35. Le Voyer T, Rouse J, Lu Z, Lifsted T, Williams M, Hunter KW. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation

associated with decreased microvessel density. Genomics 2001;74:253–61.

36. Webster MA, Hutchinson JN, Rauh MJ, et al. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344–59.

37. Danilkovitch A, Donley S, Skeel A, Leonard EJ. Two independent signaling pathways mediate the antiapoptotic action of macrophage-stimulating protein on epithelial cells. Mol Cell Biol 2000;20:2218–27.

38. Lifsted T, Le Voyer T, Williams M, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998;77:640–4.

39. Le Voyer T, Lu Z, Babb J, Lifsted T, Williams M, Hunter K. An epistatic interaction controls the latency

of a transgene-induced mammary tumor. Mamm Genome 2000;11:883–9.

40. Neznanov N, Man AK, Yamamoto H, Hauser CA, Cardiff RD, Oshima, RG. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 1999;59:4242–6.

41. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000;6:306–12.

42. Baribault H, Wilson-Heiner M, Muller W, Penner J, Bakhiet N. Functional analysis of mouse keratin 8 in polyoma middle T-induced mammary gland tumours. Transgenic Res 1997;6:359–67.

43. Vomachka AJ, Pratt SL, Lockefeer JA, Horseman ND. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 2000;19:1077–84.